Clinical and biological significance of hepsin overexpression in breast cancer

Journal of Investigative Medicine

Volumn 59, Issue 5, 2011, Pages 803-810

  Xing, Peng ^a   Li, Ji Guang ^a   Jin, Feng ^a   Zhao, Ting Ting ^a   Liu, Qun ^a   Dong, Hui Ting ^a   Wei, Xiao Lin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Clinical significance; Hepsin; Invasion; Proliferation

Indexed keywords

ESTROGEN RECEPTOR; HEPSIN; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; WESTERN BLOTTING; BREAST CANCER CELL LINE; CANCER PATIENT; FEMALE; GENE SILENCING; IMMUNOREACTIVITY; MALE; MIDDLE AGED; UPREGULATION;

EID: 85047689456     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31821451a1     Document Type: Article

References (41)

1. Parker B, Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther. 2003;2:14-21.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-572. (Pubitemid 37328923)
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458. (Pubitemid 37328849)
4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336. (Pubitemid 121001258)
5. Yoon SO, Park SJ, Yun CH, et al. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36:128-137.
6. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997;57:2884-2887. (Pubitemid 27315033)
7. Klezovitch O, Chevillet J, Mirosevich J, et al. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6:185-195. (Pubitemid 39485690)
8. Leytus SP, Loeb KR, Hagen FS, et al. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 1988;27:1067-1074. (Pubitemid 18053001)
9. Kurachi K, Torres-Rosado A, Tsuji A. Hepsin. Methods Enzymol. 1994;244:100-114.
10. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826. (Pubitemid 32801464)
11. Chen Z, Fan Z, McNeal JE, et al. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol. 2003;169:1316-1319. (Pubitemid 36323775)
12. Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol. 2001;166:2171-2177. (Pubitemid 33065250)
13. Xuan JA, Schneider D, Toy P, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 2006;66:3611-3619.
14. Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 2007;98:491-498. (Pubitemid 46562738)
15. Roemer A, Schwettmann L, Jung M, et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol. 2004;172:2162-2166. (Pubitemid 39507483)
16. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
17. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(suppl 3): S1-S22.
18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. New York, NY: Springer; 2002:223-240.
19. Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer. 2010;10:225.
20. Li X, Shen L, Zhang J, et al. Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res. 2007;67:8716-8724. (Pubitemid 47437447)
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
22. Stephan C, Yousef GM, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol. 2004;171:187-191. (Pubitemid 37549120)
23. Matsuo T, Nakamura K, Takamoto N, et al. Expression of the serine protease hepsin and clinical outcome of human endometrial cancer. Anticancer Res. 2008;28:159-164. (Pubitemid 351362896)
24. Tozlu S, Girault I, Vacher S, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer. 2006;13:1109-1120. (Pubitemid 46212566)
25. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1:227-241. (Pubitemid 14189661)
26. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284-1291.
27. Nandana S, Ellwood-Yen K, Sawyers C, et al. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate. 2010;70:591-600.
28. Miao J, Mu D, Ergel B, et al. Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer. 2008;123:2041-2047.
29. Li W, Wang BE, Moran P, et al. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res. 2009;69:8395-8402.
30. Herter S, Piper DE, Aaron W, et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 2005;390:125-136. (Pubitemid 41192238)
31. Moran P, Li W, Fan B, et al. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem. 2006;281:30439-30446. (Pubitemid 44596152)
32. Tripathi M, Nandana S, Yamashita H, et al. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem. 2008;283:30576-30584.
33. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer. 2010;46:1260-1270.
34. Elliott BE, Hung WL, Boag AH, et al. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 2002;80:91-102. (Pubitemid 34258657)
35. Jiang W, Hiscox S, Matsumoto K, et al. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29:209-248. (Pubitemid 29158969)
36. Sheen-Chen SM, Liu YW, Eng HL, et al. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:715-717.
37. Huang HY, Jiang ZF, Li QX, et al. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest. 2010;28:689-697.
38. Nakamura K, Takamoto N, Abarzua F, et al. Hepsin inhibits the cell growth of endometrial cancer. Int J Mol Med. 2008;22:389-397.
39. Torres-Rosado A, O'Shea KS, Tsuji A, et al. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A. 1993;90:7181-7185. (Pubitemid 23222413)
40. Nakamura K, Nasu Y, Hongo A, et al. Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int J Oncol. 2006;28:393-398.
41. Srikantan V, Valladares M, Rhim JS, et al. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 2002;62:6812-6816. (Pubitemid 35424064)